Method of treating blepharitis
View Patent ↗The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.
1. A method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject, comprising:
identifying a subject suffering from non-infectious, inflammatory chronic posterior blepharitis, and
topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount of azithromycin.
2. The method according to claim 1 , wherein said effective amount of azithromycin is about 0.5-1.5% (w/v).
3. The method according to claim 2 , wherein said effective amount of azithromycin is about 1% (w/v).
4. The method according to claim 1 , wherein said azithromycin is formulated in polycarbophil, edetate disodium, sodium chloride, and water.
5. The method according to claim 1 , wherein said subject is administered with the pharmaceutical formulation for at least two weeks.
6. The method according to claim 1 , wherein said subject is administered with the pharmaceutical formulation for at least a month.
7. The method according to claim 1 , further comprises the step of treating the subject with a mechanical therapy.
8. A method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject, comprising:
identifying a subject suffering from non-infectious, inflammatory chronic posterior blepharitis, and
topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount of azithromycin for more than two weeks.
9. The method according to claim 8 , wherein said effective amount of azithromycin is about 0.5-1.5% (w/v).
10. The method according to claim 9 , wherein said effective amount of azithromycin is about 1% (w/v).
11. The method according to claim 8 , wherein said azithromycin is formulated in polycarbophil, edetate disodium, sodium chloride, and water.
12. The method according to claim 8 , wherein said subject is administered with the pharmaceutical formulation for at least three weeks.
13. The method according to claim 12 , wherein said subject is administered with the pharmaceutical formulation for at least four weeks.
14. The method according to claim 8 , further comprises the step of treating the subject with a mechanical therapy.
15. A method for treating inflammatory chronic posterior blepharitis in a subject, comprising:
identifying a subject suffering from non-infectious, inflammatory chronic posterior blepharitis, and
topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin intermittently for over two weeks.
16. The method according to claim 15 , wherein the pharmaceutical formulation is topically administered intermittently after the initial daily dosing for two weeks.
17. A method for treating dry eye secondary to non-infectious, inflammatory blepharitis in a subject, comprising:
identifying a subject suffering from dry eye secondary to non-infectious, inflammatory blepharitis, and
topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin.
18. The method according to claim 17 , wherein said effective amount of azithromycin is about 0.5-1.5% (w/v).
19. The method according to claim 17 , wherein said effective amount of azithromycin is about 1% (w/v).
20. The method according to claim 17 , wherein said subject is administered with the pharmaceutical formulation daily or intermittently for more than two weeks.
21. A method for reducing contact lens intolerance of a subject due to non-infectious, inflammatory blepharitis or dry eye secondary to non-infectious, inflammatory blepharitis, comprising:
identifying a subject suffering from contact lens intolerance due to non-infectious, inflammatory blepharitis or dry eye secondary to non-infectious, inflammatory blepharitis, and
topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin, whereby the comfortable contact lens wearing time per day in the subject is increased.